Pulmatrix, Inc.
Close on Oct 19, 2026
- Market cap
- $5.19M
- P/E (TTM)
- –
- Dividend yield
- –
About Pulmatrix
Pharmaceutical Preparations, SIC 2834
Pulmatrix, Inc. is a biopharmaceutical company focused on developing inhaled therapeutic products to prevent and treat central nervous system disorders and serious respiratory diseases. Using its proprietary dry powder delivery technology platform, iSPERSE, the company designs small, dense, and dispersible particles that deliver small or large molecule drugs into the airways without reliance on conventional lactose blends. Its proprietary clinical product pipeline includes PUR3100 for acute migraine, PUR1800 for acute exacerbations of chronic obstructive pulmonary disease, and PUR1900 for allergic bronchopulmonary aspergillosis in patients with asthma or cystic fibrosis.
The company operates its corporate office in Framingham, Massachusetts. Following a strategic review, the company agreed to merge with Cullgen Inc. and has paused active clinical development across its product pipeline while exploring opportunities to license or monetize its assets and delivery platform.
Summary of the business section of Pulmatrix's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Pulmatrix, Inc.
- Founded
- 2013
- Headquarters
- Framingham, MA
- Address
- 945 Concord Street, Suite 1217 01701
- Phone
- (888) 355-4440
- Website
- pulmatrix.com
- Employees
- 2, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, New York, NY
Stock & identifiers
- Ticker
- PULM
- Exchange
- Nasdaq
- IPO date
- Mar 21, 2014
- Shares outstanding
- 4M, Aug 13, 2026
- Public float
- $25.20M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Mar 29, 2022; 1-for-20 reverse, Mar 1, 2022; 1-for-10 reverse, Feb 19, 2019; 1-for-10 reverse, Feb 6, 2019; 1-for-2.5 reverse, Jun 16, 2015
- SEC CIK
- 1574235
- CUSIP
- 74584P301
- ISIN
- US74584P3010
- LEI
- 5299002RHCRZ9ST3GN42
- EIN
- 46-1821392
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Pulmatrix's leadership is listed in its proxy statement, last filed Nov 8, 2024.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had two full-time employees, both of whom were engaged in full-time administrative activities.”
Corporate history
Events identified from SEC filings